Allt inom Other Corporate Information

Nanexa announced today that all pharmacokinetic (PK) samples from the final dose group, 30 mg of the Phase I study for NEX-22, now have been analyzed. The results show increased exposure in line with the dose escalation and further demonstrate a controlled and prolonged release of liraglutide, which supports a one-month depot of liraglutide.

Nanexa announces that the results from the recently completed Phase I-study with NEX-22 have been approved as a Late Breaking Abstract at the prestigious ADA Congress (American Diabetes Association) held in Chicago June 20-23.